Novel Application of Lutetium‐177‐Prostate Specific Membrane Antigen (LuPSMA) Radioligand Therapy for Metastatic Synovial Sarcoma
Authors:
- 21 March 2025
- journal article
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 69 (3) , 381-385
Abstract
Intracranial synovial sarcoma is exceedingly rare, with only 24 cases reported in the literature. Given prostate specific membrane antigen (PSMA) expression is found in the neovascular endothelium of solid tumours, including sarcomas, Lutetium‐177‐PSMA (LuPSMA) presents a potential therapeutic option. The case presented here describes the first application of LuPSMA in a patient with synovial sarcoma. Our patient, a 27‐year‐old female underwent seven LuPSMA treatment cycles over the last 8 months of her life. Disease stability and prolongation in time to progression was observed across the treatment course with subjective tumour regression also seen after two cycles. Overall, our initial experience with this novel approach demonstrates proof‐of‐principle of LuPSMA treatment beyond prostate cancer, for patients with other PSMA‐expressing cancer diseases.Keywords
This publication has 7 references indexed in Scilit:
- Intracranial synovial sarcoma: A clinical, radiological and pathological study of 16 casesEuropean Journal of Surgical Oncology, 2019
- Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcomaNuklearmedizin-Nuclear Medicine, 2019
- Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNSTOncotarget, 2016
- A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin AnalogsClinical Nuclear Medicine, 2016
- Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid TumorsClinical Cancer Research, 2016
- Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid TumorsJournal of Clinical Oncology, 2007